Longevity research needs a more pragmatic approach
Most longevity research starts in animals, usually mice. But how much of that actually applies to humans? A commentary in Nature Aging makes a pointed case for raising the bar.
Nearly all longevity research begins in the laboratory with animal models. Mice are by far the most common: they are inexpensive, genetically tractable and relatively short-lived. But they are not humans. They age differently, have a different immune system, and respond to interventions in ways that are frequently not confirmed in people.
The commentary, published in Nature Aging, calls for greater pragmatism in preclinical aging research. The authors argue the field would benefit from more deliberate choices in model organisms, stricter standards for how findings are translated, and higher reproducibility requirements.
The translation problem runs deep
The translation problem is not new, but it is especially pronounced in aging research. Interventions that extend lifespan in mice frequently fail to produce the same effects in humans. Laboratory mouse strains have already been heavily genetically optimized for longevity, and laboratory conditions bear little resemblance to the complex environments in which humans live and age.
The authors suggest the field should make more deliberate choices: which model organisms are most informative for specific questions? When are mice appropriate, and when are organisms such as macaques, worms or flies better suited? These choices are not always made carefully at present.
Reproducibility needs to improve
A second concern is reproducibility. Many findings in aging research are difficult to replicate in other laboratories. The authors call for larger sample sizes, more diversity in models (including female animals and aged animals rather than exclusively young adults), and greater transparency in reporting.
This is an argument for better scientific infrastructure, not for lower ambition. The longevity field is growing rapidly and attracting billions in investment. A solid preclinical foundation makes future clinical trials more credible and more likely to succeed.